EVO
Evotec SE NASDAQ$3.12
Pre-mkt
$3.17
+1.60%
Mkt Cap $1.1B
52w Low $2.31
32.5% of range
52w High $4.80
50d MA $2.87
200d MA $3.39
P/E (TTM)
-11.0x
EV/EBITDA
-24.1x
P/B
1.4x
Debt/Equity
0.6x
ROE
—
P/FCF
-11.8x
RSI (14)
—
ATR (14)
—
Beta
1.24
50d MA
$2.87
200d MA
$3.39
Avg Volume
159.0K
About
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8, 2026 | AMC | 0.21 | 0.06 | -73.9% | 2.69 | -2.6% | -2.6% | -2.2% | +3.3% | +16.0% | +19.3% | — | — |
| Nov 5, 2025 | AMC | -0.14 | -0.14 | -1.4% | 3.35 | +0.0% | -1.2% | -8.1% | -10.7% | -11.3% | -6.3% | -6.9% | — |
| Aug 13, 2025 | AMC | -0.18 | -0.14 | +19.9% | 3.81 | +1.0% | +0.3% | -1.3% | -3.4% | -5.2% | -6.3% | -8.9% | — |
| May 6, 2025 | AMC | -0.11 | -0.20 | -77.3% | 4.05 | +2.0% | +3.0% | -3.5% | +6.2% | +3.0% | +3.7% | -1.0% | — |
| Apr 17, 2025 | AMC | 0.02 | -0.12 | -768.4% | 3.60 | -3.6% | -0.6% | +10.3% | +13.6% | +16.9% | +17.2% | +10.3% | — |
| Nov 6, 2024 | AMC | -0.08 | -0.12 | -50.0% | 3.87 | +9.6% | +9.8% | +6.7% | +25.8% | +14.7% | +17.6% | +19.1% | — |
| Aug 14, 2024 | AMC | -0.09 | -0.29 | -222.2% | 3.31 | +0.3% | -3.6% | -1.5% | -3.0% | -3.3% | -6.3% | +6.9% | — |
| May 22, 2024 | AMC | -0.03 | -0.05 | -49.6% | 5.17 | -3.7% | -4.6% | -7.7% | -6.0% | -11.4% | -12.6% | -13.3% | — |
| Feb 26, 2024 | AMC | -0.03 | -0.05 | -66.7% | 7.63 | +0.7% | +0.3% | -1.8% | -3.0% | -1.3% | -5.6% | +2.4% | — |
| Nov 8, 2023 | AMC | -0.05 | -0.12 | -140.0% | 9.27 | +5.1% | +4.0% | +0.6% | +1.3% | +8.6% | +8.1% | +4.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.81 | $3.85 | +1.0% | +0.3% | -1.3% | -3.4% | -5.2% | -6.3% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.87 | $4.24 | +9.6% | +9.8% | +6.7% | +25.8% | +14.7% | +17.6% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.31 | $3.32 | +0.3% | -3.6% | -1.5% | -3.0% | -3.3% | -6.3% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.17 | $4.98 | -3.7% | -4.6% | -7.7% | -6.0% | -11.4% | -12.6% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.23 | $5.11 | -2.3% | -2.5% | -4.0% | -0.6% | -0.8% | +0.4% |
| Aug 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.02 | $11.74 | -2.3% | -1.5% | -1.7% | -4.6% | -3.5% | -4.7% |
| Jul 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.91 | $11.97 | +0.5% | +1.3% | +2.8% | +3.4% | +3.5% | +7.1% |
| Jun 23 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $11.21 | $11.45 | +2.1% | +3.9% | -1.5% | -0.5% | +1.4% | -0.4% |
| Jun 16 | BofA Securities | Downgrade | Buy → Neutral | — | $11.85 | $11.77 | -0.7% | -1.6% | -4.1% | -3.6% | -5.4% | -1.7% |
| Jun 8 | Citigroup | Upgrade | Neutral → Buy | — | $11.26 | $12.45 | +10.6% | +10.8% | +8.4% | +10.1% | +8.2% | +4.5% |
Data updated apr 26, 2026 10:32am
· Source: massive.com